Raffles Medical Group Ltd: Segment Analysis

Raffles Medical Group Ltd (RMG) is an integrated private healthcare provider offering a range of services, from primary to tertiary care, as well as wellness and health insurance. RMG operates in five countries, including Singapore, China, Vietnam, Cambodia, and Japan. The company has a significant presence in Singapore with over 80 multi-disciplinary clinics. It also has representative offices in Indonesia, Vietnam, Cambodia, and Bangladesh, and associates throughout the Asia-Pacific region. RMG collaborates with the Ministry of Health in Singapore for emergency care services. The company classifies its operations into four reportable operational segments: Healthcare Services, Hospital Services, Investment Holdings, and Insurance Services.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

RMG is actively involved in research and development through clinical trials, which play an important role in patient care at Raffles Hospital. These trials offer patients access to new therapies that are not yet commercially available. RMG’s oncologists have substantial experience running clinical trials across multiple phases, including both investigator-initiated and industry-sponsored studies, and they also participate in large international, multi-centre Phase III trials. RMG’s R&D function is led by the Clinical Trials Unit (CTU). The CTU promotes and coordinates clinical trial activities within Raffles Hospital, acting as a resource hub that connects potential sponsors with clinician-researchers and supports clinicians in delivering high-quality trials. It also manages Institutional Review Board and regulatory submissions, oversees protocol implementation, coordinates monitoring visits, and ensures timely safety reporting. Examples of patient-accessible trials coordinated by the CTU include Phase III studies in lung cancer, breast cancer, and urothelial cancer.